Environmental, Social and Governance

« I strongly believe that the success of our company lies in its capacity to adapt to tomorrow’s challenges.

Our responsibility as a company is to provide sustainability and resilience to the pharmaceutical value chain. »

Karl Rotthier, Chief Executive Officer

A collaborative approach

Building a unique ESG strategy requires diverse inputs. So, we opened a dialogue with more than 1,200 internal and external stakeholders in 30 countries through a survey.

Employees, clients, suppliers, investors, non-profits and others were called upon to share what they expect from an innovative, sustainable industry leader. Their insight was invaluable and gave us a well-rounded foundation for shaping our key commitments.

The findings of our global survey helped to define our ESG priorities. The resounding takeaway was that expectations are at an all-time high. We look forward to rising to the occasion. We’ve identified a range of priorities, which align along 4 commitments.

Our four commitments

Learn more

Our stakeholders

ESG is about taking our stakeholders expectations into our strategy. Who are they?

Developing a differentiating ESG strategy requires a wide range of contributors. 
Therefore, in 2021, we opened a dialogue with over 1,200 internal and external stakeholders through a survey covering 30 countries. 
The responses to this survey have helped us define our main commitments.

Materiality matrix

What are our stakeholders' most material expectations?